BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/30/2015 2:11:00 PM | Browse: 969 | Download: 1504
Publication Name World Journal of Gastroenterology
Manuscript ID 13660
Country Japan
Received
2014-08-29 10:49
Peer-Review Started
2014-08-31 14:55
To Make the First Decision
2014-09-27 15:48
Return for Revision
2014-10-29 11:15
Revised
2014-12-09 23:07
Second Decision
2015-01-07 08:39
Accepted by Journal Editor-in-Chief
2015-01-10 00:37
Accepted by Company Editor-in-Chief
2015-01-21 17:14
Articles in Press
2015-01-21 17:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
2015-02-08 22:52
Typeset the Manuscript
2015-04-14 20:08
Publish the Manuscript Online
2015-04-20 15:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Prospective Study
Article Title Impact of direct acting antiviral-based triple therapy on the serum alpha-fetoprotein level
Manuscript Source Unsolicited Manuscript
All Author List Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata and Jun Hayashi
Funding Agency and Grant Number
Corresponding Author Norihiro Furusyo, MD, PhD, Department of General Internal Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. furusyo@gim.med.kyushu-u.ac.jp
Key Words Chronic hepatitis C; Hepatocellular carcinoma; Direct-acting antiviral agents; Telaprevir; Serum alpha-fetoprotein
Core Tip The serum concentration of alpha-fetoprotein (AFP) is often elevated in patients with hepatocellular carcinoma (HCC), and a high AFP level has been reported to be a risk factor for the development of HCC by chronic hepatitis C patients. A recently introduced direct-acting antiviral agent, telaprevir (TVR), has been included in triple therapy regimens that include a protease inhibitor with conventional pegylated-interferon α (PEG-IFNα) and ribavirin (RBV), which has significantly improved the sustained virological response rate, up to 80% for patients with hepatitis C virus genotype 1. Regardless of virological response, TVR-based triple therapy more effectively reduces the serum alpha-fetoprotein level than does dual therapy with PEG-IFNα and RBV.
Publish Date 2015-04-20 15:10
Citation Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696-4706
URL http://www.wjgnet.com/1007-9327/full/v21/i15/4696.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i15.4696
Full Article (PDF) WJG-21-4696.pdf
Full Article (Word) WJG-21-4696.doc
Manuscript File 13660-Review.docx
Answering Reviewers 13660-Answering reviewers.pdf
Biostatistics Review Certificate 13660-Biostatistics statement.pdf
Clinical Trial Registration Statement 13660-Clinical trial registration.pdf
Conflict-of-Interest Disclosure Form 13660-Conflict-of-interest statement.pdf
Copyright License Agreement 13660-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s) 13660-Clinical trial registration.pdf
Institutional Review Board Approval Form or Document 13660-Institutional review board statement.pdf
Peer-review Report 13660-Peer-review(s).pdf
Scientific Misconduct Check 13660-CrossCheck.jpg
Scientific Editor Work List 13660-Scientific editor work list.pdf